ClinicalTrials.gg
RecruitingNCT07457229Updated May 8, 2026

Radiprodil in Participants With Hepatic Impairment

A Phase 1 interventional study of Radiprodil in Hepatic Impairment, sponsored by GRIN Therapeutics, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by GRIN Therapeutics, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This Phase 1, open-label study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of radiprodil in adults with varying degrees of hepatic impairment compared with healthy participants. Radiprodil is being developed as a potential treatment for GRIN-related neurodevelopmental disorders, tuberous sclerosis complex, and focal cortical dysplasia.

Approximately 40 adults aged 18 to 75 years will be enrolled into five cohorts based on liver function (mild, moderate, or severe hepatic impairment) or healthy status. Participants will receive a single 15 mg oral dose of radiprodil and remain in the clinical research unit for intensive PK and safety monitoring through Day 6.

The primary objective is to characterize the PK profile of radiprodil in participants with hepatic impairment compared with healthy participants. Safety and tolerability will also be assessed. Results from this study will help determine whether dose adjustments are needed in individuals with impaired liver function.

Read the detailed description

This is a Phase 1, open-label, two-arm study designed to assess the pharmacokinetics (PK), safety, and tolerability of a single oral dose of radiprodil in adults with varying degrees of hepatic impairment compared with matched healthy participants.

Up to 40 participants aged 18 to 75 years will be enrolled across five cohorts. Participants will include individuals with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment, as well as healthy participants matched for age, sex, and body mass index where feasible.

The study consists of a Screening Period (Days -28 to -2), check-in on Day -1, and a Treatment Period. Participants will be confined to the clinical research unit from Day -1 through completion of study assessments on Day 6. On Day 1, all participants will receive a single oral dose of radiprodil 15 mg administered as an oral suspension.

Serial blood samples will be collected to determine plasma concentrations of radiprodil and its major metabolites. Key PK parameters include area under the concentration-time curve (AUC), maximum observed concentration (Cmax), time to maximum concentration (Tmax), terminal half-life (t½), apparent clearance (CL/F), and apparent volume of distribution (Vz/F).

Safety and tolerability will be evaluated throughout the study by monitoring adverse events, vital signs, electrocardiograms, clinical laboratory tests, physical examinations, and Columbia Suicide Severity Rating Scale assessments.

Hepatic impairment can alter the metabolism and exposure of many drugs. Because radiprodil is primarily eliminated via hepatic metabolism, this study is intended to characterize the effect of liver impairment on radiprodil exposure and to inform potential dosing recommendations for future clinical use.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic impairment
  • Radiprodil
03

In context

Lead sponsor

GRIN Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 to 75 years, inclusive, at Screening.
  • (BMI) within the range specified in the protocol.
  • Participants with hepatic impairment must have stable mild ( Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment, as applicable to cohort assignment.
  • Healthy participants must be medically healthy with no abnormalities as determined by the investigator.
  • Participants must be willing and able to comply with all study procedures and confinement requirements.
  • Participants of must agree to use highly effective methods as defined in the protocol.
  • Participants must provide written prior to any study procedures

Exclusion criteria

Exclusion Criteria:

  • History or presence of medical conditions that could interfere with study participation or interpretation of results.
  • Positive test for drugs of abuse, alcohol, or cotinine (where applicable) at Screening or check-in.
  • Positive serology for , surface antigen, or virus.
  • Clinically significant abnormal laboratory values, vital signs, or findings at Screening or Day -1, as judged by the investigator.
  • Use of prohibited concomitant medications or substances that may interfere with radiprodil metabolism.
  • Pregnant or breastfeeding women.
  • Participation in another clinical study or receipt of an product within the protocol-specified timeframe prior to dosing.
  • Any condition that, in the opinion of the investigator or sponsor, would make participation not in the best interest of the participant or could confound study results.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Mild Hepatic Impairment

    Participants with mild hepatic impairment (Child-Pugh Class A).

    Drug: Radiprodil

  • Experimental
    Moderate Hepatic Impairment

    Participants with moderate hepatic impairment (Child-Pugh Class B).

    Drug: Radiprodil

  • Experimental
    Healthy Participants (Matched to Mild/Moderate)

    Healthy participants matched to the mild and moderate hepatic impairment cohorts by age, sex, and body mass index where feasible.

    Drug: Radiprodil

  • Experimental
    Severe Hepatic Impairment

    Participants with severe hepatic impairment (Child-Pugh Class C).

    Drug: Radiprodil

  • Experimental
    Healthy Participants (Matched to Severe)

    Healthy participants matched to the severe hepatic impairment cohort by age, sex, and body mass index where feasible.

    Drug: Radiprodil

Interventions

  • Radiprodil will be administered as a single oral dose of 15 mg (2.0 mL of 7.5 mg/mL oral suspension) on Day 1 under fed conditions. Participants will fast overnight for at least 10 hours prior to dosing and consume a standard breakfast approximately 30 minutes before administration. Study drug will be administered with approximately 240 mL of water. All participants across cohorts will receive the same single-dose regimen.

    Also known as: RGH-896, Radiprodil oral suspension

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of Radiprodil

    Plasma AUClast of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  2. Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of Radiprodil

    Plasma AUCinf of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  3. Maximum Observed Plasma Concentration (Cmax) of Radiprodil

    Plasma Cmax of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  4. Time to Maximum Observed Plasma Concentration (Tmax) of Radiprodil

    Plasma Tmax of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  5. Time Before First Quantifiable Plasma Concentration (Tlag) of Radiprodil

    Plasma Tlag of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  6. Apparent Total Body Clearance (CL/F) of Radiprodil

    Apparent total body clearance of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  7. Apparent Volume of Distribution Based on the Terminal Phase (Vz/F) of Radiprodil

    Apparent volume of distribution of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  8. Terminal Elimination Half-Life (t½) of Radiprodil

    Plasma terminal elimination half-life of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of FBPO

    Plasma AUClast of the radiprodil major metabolite FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  2. Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of FBPO

    Plasma AUCinf of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  3. Maximum Observed Plasma Concentration (Cmax) of FBPO

    Plasma Cmax of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  4. Time to Maximum Observed Plasma Concentration (Tmax) of FBPO

    Plasma Tmax of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  5. Time Before First Quantifiable Plasma Concentration (Tlag) of FBPO

    Plasma Tlag of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  6. Terminal Elimination Half-Life (t½) of FBPO

    Plasma terminal half-life of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  7. Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of ORR-S

    Plasma AUClast of the radiprodil major metabolite ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  8. Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of ORR-S

    Plasma AUCinf of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  9. Maximum Observed Plasma Concentration (Cmax) of ORR-S

    Plasma Cmax of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  10. Time to Maximum Observed Plasma Concentration (Tmax) of ORR-S

    Plasma Tmax of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  11. Time Before First Quantifiable Plasma Concentration (Tlag) of ORR-S

    Plasma Tlag of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  12. Terminal Elimination Half-Life (t½) of ORR-S

    Plasma terminal half-life of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.

    Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

  13. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Incidence of treatment-emergent adverse events following a single oral dose of radiprodil, summarized by system organ class and preferred term.

    Time frame: Day 1 through Day 6 (120 hours post-dose)

  14. Number of Participants With Serious Adverse Events (SAEs)

    Incidence of serious adverse events following a single oral dose of radiprodil.

    Time frame: Day 1 through Day 6 (120 hours post-dose)

  15. Number of Participants With Adverse Events Leading to Discontinuation

    Incidence of participants who discontinue the study due to an adverse event following a single oral dose of radiprodil.

    Time frame: Day 1 through Day 6 (120 hours post-dose)

  16. Change From Baseline in Systolic Blood Pressure (mmHg)

    Change from baseline in systolic blood pressure following a single oral dose of radiprodil.

    Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)

  17. Change From Baseline in Diastolic Blood Pressure (mmHg)

    Change from baseline in diastolic blood pressure following a single oral dose of radiprodil.

    Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)

  18. Change From Baseline in Heart Rate (beats per minute)

    Change from baseline in heart rate following a single oral dose of radiprodil.

    Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)

  19. Change From Baseline in Respiratory Rate (breaths per minute)

    Change from baseline in respiratory rate following a single oral dose of radiprodil.

    Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)

  20. Change From Baseline in Body Temperature (°C)

    Change from baseline in body temperature following a single oral dose of radiprodil.

    Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)

  21. Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) (milliseconds)

    Change from baseline in QT interval corrected using Fridericia's formula (QTcF) following a single oral dose of radiprodil.

    Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)

  22. Number of Participants With Clinically Significant Laboratory Abnormalities

    Incidence of participants with laboratory values meeting predefined criteria for clinical significance across hematology, serum chemistry, coagulation, and urinalysis following a single oral dose of radiprodil.

    Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)

  23. Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) score following a single oral dose of radiprodil.

    Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 9, 2026
StartActual
Mar 3, 2026
Primary completionEst.
May 2027
CompletionEst.
Aug 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07457229
Lead sponsor
GRIN Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Mar 3, 2026
Primary completion
May 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
May 8, 2026

Study contacts

Laura Bardell
Contact
ClinicalTrials@GrinTherapeutics.com
+1-877-225-0014
Aneeta Saxena
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Radiprodil

Start the discussion